Tilia Fiduciary Partners Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 17.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,750 shares of the medical research company’s stock after purchasing an additional 837 shares during […]
The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.
Confluence Investment Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 2nd quarter, Holdings Channel reports. The fund acquired 84,001 shares of the medical research company’s stock, valued at approximately $17,661,000. Several other institutional investors and hedge funds have also made changes to their positions in […]
StockNews.com upgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a hold rating to a buy rating in a report released on Sunday morning. Several other analysts have also recently commented on the company. Bank of America increased their target price on Charles River Laboratories International from $235.00 to $245.00 and gave […]
Sandler Capital Management lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 77.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,237 shares of the medical research company’s stock after selling 94,163 shares during the […]